Maligne Lymphome: Individualisierte Therapie in Abhängigkeit von biologischen und klinischen Risikofaktoren

Schlüsselwörter

Hodgkin-Lymphom - follikuläres Lymphom - Morbus Waldenström - Mantelzell-Lymphom

Key words

Hodgkin’s lymphoma - follicular lymphoma - Waldenstroem’s macroglobulinemia - mantle cell lymphoma

• Literatur

• 1 Ardeshna KM, Quian W, Smith P et al. An intergroup randomized trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2, and 3a): a preliminary analysis. 52nd ASH Annual Meeting 2010; Abstract 6
• 2 Younes A, Gopal AK, Smith SE et al. Results of a pivotal phase II ­study of brentuximab vedotin for patients with relapsed or refractory Hodgkin‘s lymphoma. J Clin Oncol 2012; 30: 2183-2189
• 3 Fernandez V, Salamero O, Espinet B et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010; 70: 1408-1418
• 4 Feuerlein K, Zucca E, Ghielmini M. First-line treatment of follicular lymphoma. A patient-oriented algorithm. Leuk Lymphoma 2009; 50: 225-234
• 5 Advani RH, Buggy JJ, Sharman JP et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88-94
• 6 Ghobrial IM, Hong F, Padmanabhan S et al. Phase II trial of weekly Bortezomib in combination with Rituximab in relapsed or relapsed and refractory waldenström macroglobulinemia. JCO 2010; 28: 1422
• 7 Kahl B, Byrd JC, Flinn I et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-Kinase P110δ in patients with relapsed or refractory non-hodgkin lymphoma. ASH 2010; Abstract 1777
• 8 Kastritis E, Kyrtsonis MCH, Hadjiharissi E et al. Validation of the International Prognostic Scoring System (IPSS) for waldenstrom´s macroglobulinemia (WM) and the importance of serum lactat dehydrogenase (LDH). Leuk Res 2010; 34: 1340
• 9 Martinelli G, Schmitz SF, Utinger U et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. JCO 2010; 28: 4480
• 10 Hermine O, Hoster E, Walewski J et al. Alternating Courses of 3× CHOP and 3× DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analyses of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). 54th ASH Annual Meeting and Exposition, Atlanta, December 2012; 151
• 11 Peyrade F, Jardin F, Thieblemont C et al. Groupe d‘Etude des Lymphomes de l‘Adulte (GELA) investigators. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011; 12: 460-468
• 12 Pott C, Hoster E, Delfau-Larue MN et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010; 115: 3215
• 13 Pugh TJ, Ballonoff A, Newman F et al. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis. Cancer 2010; 116: 3843
• 14 Récher C, Coiffier B, Haioun C et al. Groupe d‘Etude des Lymphomes de l‘Adulte. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011; 378: 1858-1867
• 15 Salles G, Seymour JF, Offner F et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42-51
• 16 Scholz CW, Pinto A, Likhesch W et al. (90)Yttrium-ibritumomab-­tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol 2013; 31: 308-313